Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure

Kirstie A De Jong; Viacheslav O Nikolaev

doi:10.1111/febs.15706

Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure

Standard

Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure. / De Jong, Kirstie A; Nikolaev, Viacheslav O.

In: FEBS J, Vol. 288, No. 23, 12.2021, p. 6603-6622.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

De Jong, KA & Nikolaev, VO 2021, 'Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure', FEBS J, vol. 288, no. 23, pp. 6603-6622. https://doi.org/10.1111/febs.15706

APA

De Jong, K. A., & Nikolaev, V. O. (2021). Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure. FEBS J, 288(23), 6603-6622. https://doi.org/10.1111/febs.15706

Vancouver

De Jong KA, Nikolaev VO. Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure. FEBS J. 2021 Dec;288(23):6603-6622. https://doi.org/10.1111/febs.15706

Bibtex

@article{582f7af73d514405a2e67b30c2f274e8,

title = "Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure",

abstract = "Heart failure with preserved ejection fraction (HFpEF) will soon take over as the predominant form of heart failure. This is largely driven by the continuing increased incidences of obesity and type 2 diabetes (T2D), which promote HFpEF in the absence of pressure overload stresses. With beta-blockers showing little effectiveness in treating obesity/T2D HFpEF and with no HFpEF-targeted drugs currently available, we are in urgent need of a better understanding of how obesity/T2D HFpEF develops and how we may treat this condition. An exciting emerging field aiming to do this focuses on the investigation of 3',5'-cyclic adenosine monophosphate (cAMP) microdomains in the heart. The previous work has largely focused on the investigation of cAMP microdomain remodelling in heart failure with reduced ejection fraction (HFrEF), with this work uncovering potential new targets for intervention strategies that otherwise would have been overlooked when studying changes in cAMP dynamics at the whole-cell level. In this review, we aimed to discuss current advancements in our understanding of cAMP microdomain remodelling in HFrEF vs that in obesity/T2D-associated HFpEF, with particular focus on the unresolved questions and limitations we face in being able to translate this knowledge.",

author = "{De Jong}, {Kirstie A} and Nikolaev, {Viacheslav O}",

note = "{\textcopyright} 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.",

year = "2021",

month = dec,

doi = "10.1111/febs.15706",

language = "English",

volume = "288",

pages = "6603--6622",

journal = "FEBS J",

issn = "1742-464X",

publisher = "Wiley-Blackwell",

number = "23",

}

RIS

TY - JOUR

T1 - Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure

AU - De Jong, Kirstie A

AU - Nikolaev, Viacheslav O

PY - 2021/12

Y1 - 2021/12

N2 - Heart failure with preserved ejection fraction (HFpEF) will soon take over as the predominant form of heart failure. This is largely driven by the continuing increased incidences of obesity and type 2 diabetes (T2D), which promote HFpEF in the absence of pressure overload stresses. With beta-blockers showing little effectiveness in treating obesity/T2D HFpEF and with no HFpEF-targeted drugs currently available, we are in urgent need of a better understanding of how obesity/T2D HFpEF develops and how we may treat this condition. An exciting emerging field aiming to do this focuses on the investigation of 3',5'-cyclic adenosine monophosphate (cAMP) microdomains in the heart. The previous work has largely focused on the investigation of cAMP microdomain remodelling in heart failure with reduced ejection fraction (HFrEF), with this work uncovering potential new targets for intervention strategies that otherwise would have been overlooked when studying changes in cAMP dynamics at the whole-cell level. In this review, we aimed to discuss current advancements in our understanding of cAMP microdomain remodelling in HFrEF vs that in obesity/T2D-associated HFpEF, with particular focus on the unresolved questions and limitations we face in being able to translate this knowledge.

AB - Heart failure with preserved ejection fraction (HFpEF) will soon take over as the predominant form of heart failure. This is largely driven by the continuing increased incidences of obesity and type 2 diabetes (T2D), which promote HFpEF in the absence of pressure overload stresses. With beta-blockers showing little effectiveness in treating obesity/T2D HFpEF and with no HFpEF-targeted drugs currently available, we are in urgent need of a better understanding of how obesity/T2D HFpEF develops and how we may treat this condition. An exciting emerging field aiming to do this focuses on the investigation of 3',5'-cyclic adenosine monophosphate (cAMP) microdomains in the heart. The previous work has largely focused on the investigation of cAMP microdomain remodelling in heart failure with reduced ejection fraction (HFrEF), with this work uncovering potential new targets for intervention strategies that otherwise would have been overlooked when studying changes in cAMP dynamics at the whole-cell level. In this review, we aimed to discuss current advancements in our understanding of cAMP microdomain remodelling in HFrEF vs that in obesity/T2D-associated HFpEF, with particular focus on the unresolved questions and limitations we face in being able to translate this knowledge.

U2 - 10.1111/febs.15706

DO - 10.1111/febs.15706

M3 - SCORING: Review article

C2 - 33415835

VL - 288

SP - 6603

EP - 6622

JO - FEBS J

JF - FEBS J

SN - 1742-464X

IS - 23

ER -